Copy and Edit

Test of Nuclear Medicine- Oncology 5th Year PMU

Description

Test of Nuclear Medicine- Oncology 5th Year PMU
Med Student
Quiz by Med Student , updated more than 1 year ago
Med Student
Created by Med Student over 4 years ago
2075
10
0

Resource summary

Question 1

Question
Which are the main goals of nuclear oncology
Answer
  • Imaging of the functional activity and the degree of proliferation of the tumor
  • The degree of malignant tumor spread: lymphogenic and haematogenic
  • Imaging and quantitative assessment of the effect from chemo- and hormone-therapy
  • All answers are correct

Question 2

Question
The scanning systems used in nuclear medicine are based on the principle of
Answer
  • Emission of Gamma-rays from the scanning system
  • Transition of Roentgen-rays through the patient's body
  • Detection of Gamma-rays or positron emission (pairs of annihilation Gamma-rays) emitted from the studied object
  • All answers are correct

Question 3

Question
Which methods of nuclear medicine are used for diagnosis of malignant tumours
Answer
  • PET/CT
  • Gamma camera scintigraphy
  • Radioimmunoassay of tumour markers
  • All answers are correct

Question 4

Question
Nuclear medicine diagnosis provides
Answer
  • Metabolic imaging
  • Quantitative assessment of physiological processes in the human body
  • Targeted planning of radiotherapy
  • All answers are correct

Question 5

Question
Nuclear medicine applies
Answer
  • Unsealed radioactive sources for medical diagnosis
  • Unsealed radioactive sources for radiotherapy
  • Sealed radioactive sources for medical diagnosis and therapy
  • Correct answers- a) and b)

Question 6

Question
PET/CT is a multimodality system combining
Answer
  • PET scanner with low-dose CT for improvement of the quality and precise localization of the functional image
  • PET scanner with possibility for additional targeted diagnostic contrast CT
  • Acquisition and fusion of functional and structural-anatomic images
  • All answers are correct

Question 7

Question
CT and PET scans demonstrate different aspects of disease indicating regions with
Answer
  • Altered metabolism (PET) and areas of structural change (CT)
  • Altered metabolism (CT) and areas of structural change (PET)
  • Altered metabolism (PET) and areas of structural change (PET)
  • Altered metabolism (CT) and areas of structural change (CT)

Question 8

Question
Which of the following diagnostic methods belong to modern Nuclear medicine
Answer
  • PET/CT
  • SPECT/CT
  • PET/MRI
  • All answers are correct

Question 9

Question
Which radionuclides are used for metabolic brachytherapy
Answer
  • High-energy γ (Gamma) emitters
  • β- (Beta)-emitters
  • β- (Beta) and γ (Gamma)-emitters
  • Correct answers — b) and c)

Question 10

Question
Nuclear medicine methods are used for
Answer
  • Diagnosis of benign and malignant diseases
  • Treatment of benign diseases
  • Treatment of malignant diseases
  • All answers are correct

Question 11

Question
PET /CT imaging has demonstrated significant application in the following clinical areas EXCEPT
Answer
  • Oncology
  • Cardiology
  • Pulmonology
  • Neurology

Question 12

Question
Which radiopharmaceuticals are used for tumor-specific imaging
Answer
  • 131 I- NaI
  • III In-Octreoscan
  • 99m Tc-Tetrofosmin
  • All answers are correct

Question 13

Question
Malignant tumors present on scintigraphy with tumor-specific radiopharmaceuticals as
Answer
  • Zones of increased uptake of the radiopharmaceuticals
  • Zones of decreased uptake of the radiopharmaceuticals
  • Zones of absent uptake of the radiopharmaceuticals
  • Zones of normal uptake of the radiopharmaceuticals

Question 14

Question
The most frequently used radiopharmaceutical for PET/CT imaging is
Answer
  • 18F-FDG
  • 99mTc-Pertechnetate
  • 131-Iodine — Nal
  • No correct answer

Question 15

Question
The PET scanner is detector of
Answer
  • Alfa-particles
  • Beta-particles
  • Pairs of annihilation Gamma rays
  • All answers are correct

Question 16

Question
Bone scintigraphy is
Answer
  • Highly specific diagnostic method
  • Highly sensitive diagnostic method
  • Highly sensitive and highly specific diagnostic method
  • Non-sensitive and non-specific diagnostic method

Question 17

Question
The main indication for bone scintigraphy is
Answer
  • Inflammatory bore disorders
  • Early detection of bone metastases
  • Benign bone tumors
  • Degenerative joint disorders

Question 18

Question
Metabolic brachytherapy with Metastron (89 Stroncium) is applied in patients with
Answer
  • Bone metastases
  • Pulmonary metastases
  • Brain metastases
  • Liver metastases

Question 19

Question
Contraindication for metabolic brachytherapy in patients with metastatic bone disease is
Answer
  • Advanced stage of the disease
  • Considerable myelo-depression
  • Inflammatory conditions
  • All answers are correct

Question 20

Question
Differentiated Thyroid cancer after total thyroidectomy and manifested distant haematogenic metastases is treated successfully with
Answer
  • Operation
  • Radioiodine metabolic brachytherapy
  • Chemotherapy
  • Electron therapy

Question 21

Question
Which of the following statements describing 18-F FDG PET imaging in thyroid carcinoma is FALSE
Answer
  • 18-F FDG PET can be negative in well differentiated types
  • 18-F FDG PET negative lesions are more likely to be resistant to 1-131 treatment
  • 18-F FDG uptake is proportional to Iodine uptake
  • 18-F FDG PET may not be accurate in patient with Tg levels below 2 ng/ dL

Question 22

Question
The most specific method for follow-up after treatment of Differentiated thyroid cancer is
Answer
  • Roentgenography
  • Thyroglobulin
  • Whole-body scintigraphy with 131-Iodine
  • Correct answers — b) and c)

Question 23

Question
A Thyroid cancer presents on the conventional scintigram with 99mTc as
Answer
  • Hot nodule
  • Warm nodule
  • Cold nodule
  • All answers are correct

Question 24

Question
Which histologic types of Thyroid cancer COULD NOT be treated with 131-Iodine metabolic brachytherapy
Answer
  • Papillary
  • Follicular
  • Medullary and anaplastic
  • Correct answers — a) and b)

Question 25

Question
An oncology patient referred for PET/CT should fast prior to the appointment for at least
Answer
  • 12h
  • 8h
  • 4h
  • 2h

Question 26

Question
The recommended time interval for PET/CT. imaging after biopsy is
Answer
  • 1 week
  • 2-4 weeks
  • 2-6 months
  • more than 6 months

Question 27

Question
In order to avoid false-positive results, FDG PET/ CT scans should be performed
Answer
  • 1-2 weeks after the last cycle of chemotherapy
  • 2-4 weeks after the last cycle of chemotherapy
  • 4-6 weeks after the last cycle of chemotherapy
  • 6-8 weeks after the last cycle of chemotherapy

Question 28

Question
False-negative PET/CT scans in lung cancer imaging occur predominantly because of
Answer
  • Lesions are too big to be evaluated by PET
  • Lesions are too superficial to be evaluated by PET
  • Lesions are too small to be evaluated by PET
  • Lesions are too deep to be evaluated by PET

Question 29

Question
F-18 FDG PET/CT is considered as a superior modality, compared with CT for evaluating post-treatment response in lymphoma patients because of
Answer
  • The ability to provide anatomical information
  • The ability to differentiate viable tumour from fibrosis
  • Higher resolution
  • Shorter imaging

Question 30

Question
A breast-feeding patient referred for PET/CT imaging should
Answer
  • Discontinue breast-feeding 12 h before injection of radiotracer
  • Discontinue breast-feeding 6 h before injection of radiotracer
  • Discontinue breast-feeding for at least 6 h after injection of radiotracer
  • Discontinue breast-feeding for at least 12 h after injection of radiotracer

Question 31

Question
A PET quantifier, calculated as the tracer activity concentration within a volume of interest divided by the injected dose per unit body weight is
Answer
  • Fractional uptake value
  • Standardized upload value
  • Standardized uptake value
  • Fractionai upload value

Question 32

Question
The Standardized Uptake Value (SUV) is
Answer
  • The measured activity divided by the body mass
  • The amount of tracer needed for a particular body weight
  • The measured activity normalized for body weight and inject dose
  • The measured activity within a particular organ divided by the sampled volume

Question 33

Question
For optimal patient care and interpretation of FDG PET/CT images, the following information from the patient should be obtained
Answer
  • Breast-feeding info
  • Recent surgery info
  • Use of medication info
  • All answers are correct

Question 34

Question
FDG PET/CT provides beneficial information in all of the following areas of lymphoma evaluation EXCEPT
Answer
  • Diagnosis
  • Response to therapy
  • Recurrence detection
  • Staging

Question 35

Question
Which of the following statements correctly explains the influence of FDG PET/CT imaging on staging in patients with Hodgkin's lymphoma
Answer
  • Upstaging of approximately 15-25 % of patients
  • Down-staging in a small minority of patients
  • Upstaging in a small minority of patients
  • Down-staging of approximately 15-25 % of patients

Question 36

Question
All of the following are well-established indications for FDG PET/CT imaging in patients with recurrent colorectal carcinoma EXCEPT
Answer
  • Falling CEA levels in the absence of a known source
  • Staging recurrent colorectal carcinoma
  • Preoperative staging
  • Equivocal lesion on conventional imaging

Question 37

Question
When monitoring response to treatment with FDG PET/CT Imaging is essential to obtain
Answer
  • Baseline FDG PET/CT scan
  • Interim FDG PET/CT scan
  • FDG PET/CT scan on the last day of therapy
  • FDG PET/CT scan two days after therapy

Question 38

Question
FDG uptake by cancer cells tends to decline as
Answer
  • Blood glucose and insulin levels decrease
  • Blood glucose level decrease and insulin levels increase
  • Blood glucose and insulin levels increase
  • Blood glucose level increase and insulin levels decrease

Question 39

Question
All of the following statements describe the usefulness of FDG PET/CT imaging in malignant pleural mesothelioma (MPM) EXCEPT
Answer
  • FDG PET/CT reduces the number of futile surgical procedures
  • FDG PET/CT imaging is useful for guiding needle biopsy
  • FDG PET/CT increases the accuracy of overall MPM staging
  • High levels of FDG uptake are associated with a favourable prognosis

Question 40

Question
The intensity of FDG uptake in the majority of mesotheliomas
Answer
  • Ranges from absent to low
  • Ranges from low to moderate
  • Ranges from moderate to high
  • Is always high

Question 41

Question
Selected tumours with low FDG uptake include all of the following EXCEPT
Answer
  • Prostate carcinoma
  • Iodine-avid differentiated thyroid carcinoma
  • Metastatic liver carcinoma
  • Hepatocellular carcinoma

Question 42

Question
All of the following statements correctly describe the postsurgical 18-F FDG uptake at the intervention site EXCEPT
Answer
  • Postsurgical 18-F FDG uptake is mainly diffuse
  • Postsurgical 18-F FDG uptake corresponds to the site of surgery
  • Postsurgical 18-F FDG uptake increases in intensity with time
  • Postsurgical 18-F FDG uptake in size with time

Question 43

Question
18-F FDG PET/CT should be performed on patients previously treated for differentiated thyroid cancer when the finding of 131-I whole body scintigraphy are negative and
Answer
  • The thyroglobuline (Tg) levels are more than 10 ng/ mL
  • The thyroglobuline (Tg) levels are less than 10 ng/ mL
  • The TSH levels are more than 30 mIU/L
  • The TSH levels are less than 30 mIU/ L

Question 44

Question
FDG PET/CT findings in anaplastic thyroid cancer can be described by all of the following EXCEPT
Answer
  • FDG PET/CT defines the local extent of disease and the presence of metastases
  • A positive PET/CT scan after therapy is linked with longer survival
  • FDG PET/CT have an impact on patients' management
  • Intense FDG uptake and volume are prognostic for a bad outcome

Question 45

Question
FDG PET/CT used in patients with suspected and residual/ recurrent gliomas is limited by
Answer
  • The low 18-F FDG uptake in normal brain tissue
  • The high 18-F FDG uptake in normal brain tissue
  • The low 18-F FDG uptake in tumour tissue
  • The high 18-F FDG uptake in tumour tissue

Question 46

Question
18-F FDG PET imaging is NOT indicated for initial staging of
Answer
  • Breast cancer
  • Hodgkin's lymphoma
  • Prostate cancer
  • Lung cancer

Question 47

Question
Which of the following statements describing 18-F FDG PET in the diagnostic work-up of patients with melanoma is FALSE
Answer
  • FDG PET is a standard modality in evaluation of recurrent melanoma
  • Melanin content influences lesion detectability by FDG PET
  • FDG PET is most valuable in stage III disease
  • FDG PET is more accurate for systemic staging than regional staging

Question 48

Question
Ovarian uptake of 18-F FDG in a postmenopausal patient indicates
Answer
  • A normal finding
  • Malignancy
  • Pregnancy
  • Benign ovarian cyst

Question 49

Question
F-18 FDG focal uptake seen 6 months after completion of radiation therapy should be considered as
Answer
  • Tumour recurrence
  • Normal finding
  • Radiation necrosis
  • Radiation pneumonitis

Question 50

Question
According to the PERCIST (PET Response Criteria in Solid Tumours) criteria for treatment response evaluation, the changes in SUVs should be assessed as
Answer
  • Percentage change in the same lesion
  • Percentage change in the “hottest” lesion
  • Value change in the same lesion
  • Value change in the “hottest” lesion
Show full summary Hide full summary

Want to create your own Quizzes for free with GoConqr? Learn more.

Similar

Anaesthesiology MCQs 1- 5th Year PMU
Med Student
Gastro-Intestinal Disorders- Clinical Pharmacology 5th Year PMU
Med Student
Infection Disorders- Clinical Pharmacology 5th Year PMU
Med Student
Oncology Final MCQs 1- 5th Year PMU
Med Student
General Physiology of the Nervous System Physiology PMU 2nd Year
Med Student
Blood MCQs Physiology PMU 2nd Year
Med Student
General Pathoanatomy Final MCQs (111-200)- 3rd Year- PMU
Med Student
General Pathoanatomy Final MCQs (401-519)- 3rd Year- PMU
Med Student
Microbiology MCQs 3rd Year Final- PMU
Med Student
Cell Physiology and General Physiology of Excitable Tissues- Physiology PMU 2nd Year
Med Student
General Pathoanatomy Final MCQs (201-300)- 3rd Year- PMU
Med Student
Browse Library